brokerbase

About tradingpattern.net

The movement of a security's price over a specific time period.

dedicated to value creation and applying the scientific method in finance

Search


www.brokerbase.ch network

WP-Cumulus by Roy Tanck and Luke Morton requires Flash Player 9 or better.

biologic equity research ¤ sandisk quartalszahlen ¤ mitel shares downgraded ¤ dow jones statistics ¤ comcast analyst ratings goldman ¤ penn west citrix ¤ comcast ¤ mcdonalds bond rating ¤ %22arctic slope regional corp%22 or %22boeing defense%22 or %22booz allen hamilton%22 or %22call henry%22 or %22ch2m hill%22 or chenega or %22chugach alaska corp%22 or %22day and zimmerman%22 or ¤ pennwest citrix ¤ google quartalszahlen ¤ dawson james camh ¤ upgrade mosaic ¤ mitel analyst ¤ celestica analysts ratings ¤ ladenburg thalmann djsp ¤ upgrade dupont ¤ market maker id ¤ raiffeisen centrobank ag rating ¤ penn west citrix login ¤
downgraded ¤ downgrade ¤ stock ¤ james ¤ ratings ¤ mitel ¤ analyst ¤ report ¤ dupont ¤ recommendation ¤ statistics ¤ login ¤ group ¤ davidson ¤ pennwest ¤ outperform ¤ penn ¤ rating ¤ upgraded ¤ rbc ¤ research ¤ buy ¤ s&p ¤ canaccord ¤ stifel ¤ securities ¤ capital ¤ for ¤ morgan ¤ equity ¤ wunderlich ¤ west ¤ nicolaus ¤ bond ¤ quartalszahlen ¤ debt ¤ comments ¤ market ¤ analysts ¤ maker ¤ dow ¤ upgrade ¤ renhe ¤ oppenheimer ¤ baird ¤ credit ¤ dawson ¤ company ¤ barclays ¤ citrix ¤ 2010 ¤ ubs ¤ pdf ¤ energy ¤

www.brokerbase.ch network - market statistics

www.brokerbase.ch network - archived market statistics

www.brokerbase.ch High dividend yield stocks

Blogroll

Recent Posts

Wikio - Top Blog Add to Technorati Favorites Bloggeramt.de blogoscoop Blogverzeichnis - Blog Verzeichnis bloggerei.de Add to Google investinformer.de - TOP100 Investment Sites Listinus Toplisten

Main | »

Dendreon – DNDN +210% – first quarter winner

By Martin | April 2, 2007

A biotechnology company, engaged in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer.

DNDN is the first quarter winner. 

The stock price surged nearly 150% on Mar. 30 after news that the U.S. Food and Drug Administration advisory committee vouched for the company’s Provenge compound – even though the prostate cancer treatment may not kill tumors. Studies suggest, however, that the drug extends peoples’ lives.

Social Bookmarks :
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Blogplay
  • Add to favorites
  • BlinkList
  • blogmarks
  • Blogosphere News
  • email
  • Faves
  • FriendFeed
  • FSDaily
  • LinkArena
  • LinkedIn
  • Live
  • MisterWong
  • MisterWong.DE
  • MSN Reporter
  • PDF
  • Ping.fm
  • Reddit
  • RSS
  • SheToldMe
  • Technorati
  • ThisNext
  • Twitter
  • Webnews.de
  • Webride
  • Wikio
  • Yahoo! Bookmarks
  • Yahoo! Buzz
  • Yigg

Topics: Healthcare | No Comments »

Trackback URL for this post: http://www.tradingpattern.net/2007/04/02/dendreon-dndn-150-first-quarter-winner/trackback/

Comments

You must be logged in to post a comment.